{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:28Z","timestamp":1788881128807,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019890","name":"University of Miyazaki Hospital","doi-asserted-by":"publisher","award":["Grant-in-Aid for Clinical Research (R6)"],"award-info":[{"award-number":["Grant-in-Aid for Clinical Research (R6)"]}],"id":[{"id":"10.13039\/100019890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Adult T-cell leukemia\/lymphoma (ATL) is a peripheral T-cell malignancy with a poor prognosis. We conducted a retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of tucidinostat in patients with relapsed\/refractory ATL who had not undergone transplantation. Between October 2021 and July 2023, 24 patients aged 41 to 88\u00a0years (median, 73.4\u00a0years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated as key outcomes. ORR and DCR reached 54.2% and 91.7%, respectively. The median PFS was 3.95\u00a0months, and OS was 8.04\u00a0months, which were not inferior to the results of a phase IIb study. The influential factors for PFS were age\u2009\u2265\u200975\u00a0years and high soluble IL-2 receptor (sIL-2R) levels above 5000 U\/mL at the start of treatment. Favorable patients without these factors achieved a PFS of 11.4\u00a0months. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed\/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.<\/jats:p>","DOI":"10.1007\/s12185-025-03963-9","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:14:16Z","timestamp":1741673656000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of tucidinostat in adult T-cell leukemia\/lymphoma in clinical practice"],"prefix":"10.1007","volume":"122","author":[{"given":"Ayako","family":"Kamiunten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-1710","authenticated-orcid":false,"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayuka","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"3","key":"3963_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481\u201392.","journal-title":"Blood"},{"issue":"3","key":"3963_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79(3):428\u201337.","journal-title":"Br J Haematol"},{"key":"3963_CR3","unstructured":"Shimoyama M. Chemotherapy of ATL. K Takatsuki (Ed), Adult T-Cell Leukemia, Oxford University Press, Oxford. 1994:221\u2013227."},{"issue":"34","key":"3963_CR4","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458\u201364. https:\/\/doi.org\/10.1200\/JCO.2007.11.9958.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3963_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ejh.13565","volume":"106","author":"M Sekine","year":"2021","unstructured":"Sekine M, Kameda T, Shide K, Maeda K, Toyama T, Kawano N, et al. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia\/lymphoma. Eur J Haematol. 2021;106(3):398\u2013407. https:\/\/doi.org\/10.1111\/ejh.13565.","journal-title":"Eur J Haematol"},{"issue":"4","key":"3963_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s12185-016-2042-y","volume":"104","author":"Y Nishi","year":"2016","unstructured":"Nishi Y, Fukushima T, Nomura S, Tomoyose T, Nakachi S, Morichika K, et al. Characterization of patients with aggressive adult T-cell leukemia-lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort. Int J Hematol. 2016;104(4):468\u201375. https:\/\/doi.org\/10.1007\/s12185-016-2042-y.","journal-title":"Int J Hematol"},{"issue":"24","key":"3963_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570\u20137. https:\/\/doi.org\/10.1182\/blood-2015-03-632489.","journal-title":"Blood"},{"issue":"4","key":"3963_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12185-023-03572-4","volume":"117","author":"H Katsuya","year":"2023","unstructured":"Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma. Int J Hematol. 2023;117(4):512\u201322. https:\/\/doi.org\/10.1007\/s12185-023-03572-4.","journal-title":"Int J Hematol"},{"issue":"4","key":"3963_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2010.315","volume":"25","author":"H Hasegawa","year":"2011","unstructured":"Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia\/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia. 2011;25(4):575\u201387. https:\/\/doi.org\/10.1038\/leu.2010.315.","journal-title":"Leukemia"},{"issue":"8","key":"3963_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/cas.12971","volume":"107","author":"H Hasegawa","year":"2016","unstructured":"Hasegawa H, Bissonnette RP, Gillings M, Sasaki D, Taniguchi H, Kitanosono H, et al. Induction of apoptosis by HBI-8000 in adult T-cell leukemia\/lymphoma is associated with activation of Bim and NLRP3. Cancer Sci. 2016;107(8):1124\u201333. https:\/\/doi.org\/10.1111\/cas.12971.","journal-title":"Cancer Sci"},{"issue":"8","key":"3963_CR11","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: Phase IIb results. Cancer Sci. 2022;113(8):2778\u201387. https:\/\/doi.org\/10.1111\/cas.15431.","journal-title":"Cancer Sci"},{"key":"3963_CR12","unstructured":"U.S. Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. USA: 2017."},{"issue":"14","key":"3963_CR13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30(14):1635\u201340. https:\/\/doi.org\/10.1200\/JCO.2011.38.2101.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3963_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.12962","volume":"166","author":"T Fukushima","year":"2014","unstructured":"Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166(5):739\u201348. https:\/\/doi.org\/10.1111\/bjh.12962.","journal-title":"Br J Haematol"},{"issue":"8","key":"3963_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342. https:\/\/doi.org\/10.1200\/JCO.2011.37.3472.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3963_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.13220","volume":"102","author":"K Ishitsuka","year":"2019","unstructured":"Ishitsuka K, Yurimoto S, Tsuji Y, Iwabuchi M, Takahashi T, Tobinai K. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2019;102(5):407\u201315. https:\/\/doi.org\/10.1111\/ejh.13220.","journal-title":"Eur J Haematol"},{"issue":"3","key":"3963_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108(3):811\u201321. https:\/\/doi.org\/10.3324\/haematol.2022.280996.","journal-title":"Haematologica"},{"issue":"8","key":"3963_CR18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.083.","journal-title":"Cell Rep"},{"issue":"10","key":"3963_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368. https:\/\/doi.org\/10.1182\/blood.2022016862.","journal-title":"Blood"},{"issue":"5","key":"3963_CR20","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2017.184564","volume":"103","author":"S Fuji","year":"2018","unstructured":"Fuji S, Utsunomiya A, Inoue Y, Miyagi T, Owatari S, Sawayama Y, et al. Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica. 2018;103(5):e211\u20134. https:\/\/doi.org\/10.3324\/haematol.2017.184564.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03963-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:18:07Z","timestamp":1750936687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3963"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03963-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Shimoda received consulting fees from Novartis Pharma, Takeda Pharmaceutical, and Bristol-Myers, all outside the submitted work, and received research grants from Perseus Proteomics, Pharma Essentia Japan KK, AbbVie GK, Astellas Pharma, MSD, Chugai Pharmaceutical, Kyowa Kirin, Pfizer, Novartis Pharma, Otsuka Pharmaceutical, Meiji Seika Pharma, and Asahi Kasei Medical, all outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}